Jaya Biosciences
Private Company
Funding information not available
Overview
Jaya Biosciences is a preclinical biotech focused on a novel approach to neurodegenerative diseases by targeting specific genetic drivers, particularly lysosomal dysfunction. Its lead candidate, JB111, is an AAV9-mediated gene therapy designed to address PPT1 haploinsufficiency in Alzheimer's disease, representing a precision medicine strategy for a subset of patients. The company is building a strong intellectual property portfolio with recent patent grants in key global markets. Backed by a team with deep experience in lysosomal biology and gene therapy, Jaya is positioning itself in the high-need but challenging field of CNS gene therapy.
Technology Platform
AAV9-mediated CNS-directed gene therapy platform targeting lysosomal gene haploinsufficiency for neurodegenerative diseases.
Opportunities
Risk Factors
Competitive Landscape
Jaya competes in the crowded neurodegenerative disease space but with a niche, genetics-focused strategy. It faces competition from both large pharma developing broad amyloid/tau therapies and other biotechs pursuing gene therapy for CNS diseases (e.g., for AAV delivery, targets like APOE). Its specific focus on PPT1 in AD is currently unique.